Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Published byKai Hyttinen Modified over 5 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Clin. Oncol. doi: /nrclinonc"— Presentation transcript:

1 Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.79
Figure 3 Regulatory considerations in trial development of drugs combined with radiotherapy Figure 3 | Regulatory considerations in trial development of drugs combined with radiotherapy. Early interactions with regulatory agencies are recommended because of the limited published regulatory guidance. CHMP, Committee for Medicinal Products for Human Use; EMA, European Medicines Agency; IND, investigational new drug; MOA, mechanism of action; MTD, maximum tolerated dose; NDA, new drug application; PI/PII/PIII, phase of development of clinical trial; RT, radiotherapy. Sharma, R. A. et. al. (2016) Clinical development of new drug–radiotherapy combinations Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Nat. Rev. Clin. Oncol. doi: /nrclinonc"

Similar presentations

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer CCOP Investigators’

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer CCOP Investigators’
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Figure 5 Identification of mucinous carcinoma

Figure 5 Identification of mucinous carcinoma
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Similar presentations

Ads by Google